《新股消息》博泰生物-B(06990.HK)公開發售下限定價60.6元 一手中籤率75%
默沙東任第二大股東的生物製藥公司科倫博泰生物-B(06990.HK)公布招股結果,每股發售價定為60.6元,為招股價範圍(60.6至72.8元)下限定價。香港公開發售部分錄得超額認購約0.27倍。每手100股計,一手中籤率75.03%,認購兩手(200股)穩獲一手。該股將於明日(11日)掛牌。聯席保薦人為高盛及中信証券。
公司是次招股引入5名基石投資者,包括母公司科倫藥業(002422.SZ)旗下科倫國際、RTW Funds、Laurion Capital Master Fund、TruMed,以及東方證券(03958.HK)與中國東航集團有份投資的匯添富,合共認購867.7萬股,佔全球發售完成後公司已發行H股約14.3%及公司已發行股本總額的4%。
此外,公司上市料淨集資約12.59億元,當中約45%將用於研發及商業化核心產品SKB264及A166;30%將用於其他主要產品的研發及商業化;12%將用於為持續開發技術平台、推進其他現有管線資產以及探索並開發新候選藥物提供資金:8%將用於為擴充產能及質量控制系統以支持後期資產的預期商業化提供資金;及5%將用於營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.